Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Tres Comorbidity Score Predicts Survival Outcomes in an International Cohort of Patients with Waldenstrom's Macroglobulinemia

Geoffrey Shouse, Shin Yeu Ong, Max J Gordon, Tanya Siddiqi, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2024-209638

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Blood (2024) 144 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2024-197987

Published: 2024

Journal Articles

Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma

Max J Gordon, Milos D Miljkovic, Samuel Ng, Rahul Lakhotia, Christopher Melani, Kevin Conlon, James D. Phelan, Bonita Bryant, Laura M Yee, Stefania Pittaluga, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski

Blood (2024) 144 (Supplement 1): 984.

https://doi.org/10.1182/blood-2024-199196

Published: 2024

Journal Articles

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Blood (2024) 144 (Supplement 1): 2958.

https://doi.org/10.1182/blood-2024-201711

Published: 2024

Journal Articles

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Blood (2024) 144 (Supplement 1): 750.

https://doi.org/10.1182/blood-2024-197956

Published: 2024

Journal Articles

Analytical Validation of a Duplex Sequencing AML Assay with a Limit of Detection Below 0.01% VAF for SNVs and Indels

Mark A. McElwain, Janice M. Olson, Camila Zanette, Karen Nguyen, Devon M. Fitzgerald, Isabel Y. Lee, Elizabeth Schmidt, Kevin C. Vavra, Laura B. Gillis, Kelly J. Gordon, Wayne B. Wakeman, Thomas H. Smith, Jesse J. Salk, Jake Higgins, Jill C. Harrell, Frances Chu, Gavin D. Meredith

Blood (2023) 142 (Supplement 1): 6020.

https://doi.org/10.1182/blood-2023-189955

Published: 2023

Journal Articles

Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies

Angela Sheng, Max J. Gordon, Sairah Ahmed, Raphael E Steiner, Paolo Strati, Jason Westin, Chitra Hosing, Partow Kebriaei, Elizabeth J Shpall, Sattva S. Neelapu, Loretta J. Nastoupil

Blood (2022) 140 (Supplement 1): 2051–2052.

https://doi.org/10.1182/blood-2022-165398

Published: 2022

Journal Articles

A Novel, Clinically Adaptable Comorbidity Assessment Tool for Non-Hodgkin Lymphoma (NHL), the Three-Factor Risk Estimate Scale (TRES): Analysis of 40,000 Older Adults Enrolled in SEER-Medicare

Max J. Gordon, Zhigang Duan, Hui Zhao, Loretta J. Nastoupil, Alessandra Ferrajoli, Alexey Danilov, Sharon Giordano

Blood (2022) 140 (Supplement 1): 1924–1925.

https://doi.org/10.1182/blood-2022-159632

Published: 2022

Journal Articles

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Blood (2022) 140 (Supplement 1): 2048–2050.

https://doi.org/10.1182/blood-2022-169872

Published: 2022

Journal Articles

Association of Non-Hodgkin Lymphoma (NHL), Comorbidity and Death Due to Other Cancers in 30,000 Older Adults from SEER-Medicare

Max J. Gordon, Zhigang Duan, Hui Zhao, Loretta J. Nastoupil, Alessandra Ferrajoli, Alexey V Danilov, Sharon Giordano

Blood (2022) 140 (Supplement 1): 8034–8035.

https://doi.org/10.1182/blood-2022-163472

Published: 2022

Journal Articles

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

Blood (2022) 140 (14): 1650–1655.

https://doi.org/10.1182/blood.2022015721

Published: 2022

Includes: Supplemental data

Journal Articles

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Blood (2022) 139 (26): 3752–3770.

https://doi.org/10.1182/blood.2021015108

Published: 2022

Includes: Supplemental data

Journal Articles

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

Max J. Gordon, Andy Kaempf, Emelie Rotbain, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Michael Choi, Jonathon B. Cohen, Deborah M. Stephens, Dan O. Persky, Krish Patel, Mazyar Shadman, Byung Park, Carsten Utoft Niemann, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2637.

https://doi.org/10.1182/blood-2021-148253

Published: 2021

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Max J. Gordon, MD, Andy Kaempf, MS, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, BS, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MDMPH, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-136808

Published: 2020

Journal Articles

Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 3483.

https://doi.org/10.1182/blood-2019-128864

Published: 2019

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 3997.

https://doi.org/10.1182/blood-2019-128632

Published: 2019

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Max J. Gordon, MD, Andy Kaempf, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MD, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4286.

https://doi.org/10.1182/blood-2019-124631

Published: 2019

Journal Articles

The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5891.

https://doi.org/10.1182/blood-2019-130249

Published: 2019

NARROW

Tres Comorbidity Score Predicts Survival Outcomes in an International Cohort of Patients with Waldenstrom's Macroglobulinemia

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Analytical Validation of a Duplex Sequencing AML Assay with a Limit of Detection Below 0.01% VAF for SNVs and Indels

A Novel, Clinically Adaptable Comorbidity Assessment Tool for Non-Hodgkin Lymphoma (NHL), the Three-Factor Risk Estimate Scale (TRES): Analysis of 40,000 Older Adults Enrolled in SEER-Medicare

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Association of Non-Hodgkin Lymphoma (NHL), Comorbidity and Death Due to Other Cancers in 30,000 Older Adults from SEER-Medicare

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only